Source:

Vermeire S, et al. OP090. Estimated effects of screening delays due to SARS-CoV-2 pandemic on colorectal cancer mortality. Presented at: UEG Week; Oct. 11-13, 2020.

Disclosures: Vermeire receives financial support from AbbVie, Takeda, Pfizer, Johnson & Johnson; receives lecture fees from Merck Sharp & Dohme Corp., AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, Johnson & Johnson, Genentech/Roche and Tillotts and is a consultant for Merck Sharp & Dohme Corp., AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, Johnson & Johnson, Genentech/Roche, Celgene, Mundipharma, Celltrion, Second Genome, Prometheus, Gilead, Galapagos, ProDigest, Abivax, GSK and Tillotts.
October 12, 2020
1 min read
Save

Subcutaneous Entyvio safe, effective for long-term maintenance of UC

Source:

Vermeire S, et al. OP090. Estimated effects of screening delays due to SARS-CoV-2 pandemic on colorectal cancer mortality. Presented at: UEG Week; Oct. 11-13, 2020.

Disclosures: Vermeire receives financial support from AbbVie, Takeda, Pfizer, Johnson & Johnson; receives lecture fees from Merck Sharp & Dohme Corp., AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, Johnson & Johnson, Genentech/Roche and Tillotts and is a consultant for Merck Sharp & Dohme Corp., AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, Johnson & Johnson, Genentech/Roche, Celgene, Mundipharma, Celltrion, Second Genome, Prometheus, Gilead, Galapagos, ProDigest, Abivax, GSK and Tillotts.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The interim analysis of subcutaneous Entyvio demonstrates the treatment is safe and effective for long-term maintenance of ulcerative colitis, according to results presented at UEG Week.

“These findings support the use of vedolizumab SC (vedolizumab, Takeda) at a dose of 108 mg every 2 weeks as a safe and effective alternative to IV administration for long-term maintenance treatment of patients with UC,” Séverine Vermeire, MD, PhD, from the University Hospital Leuven, Belgium.

The VISIBLE open-label extension is an ongoing, multinational, multicenter phase 3 study of patients with UC enrolled for the VISIBLE 1 study and patients with Crohn’s disease enrolled in VISIBLE 2.

There were 288 patients from VISIBLE 1 who completed 52 weeks of treatment and were enrolled in VISIBLE OLE. They received vedolizumab 108 mg subcutaneous (SC) every 2 weeks. Nonrandomized week 14 responders from VISIBLE 1 after receiving an additional third IV induction dose of vedolizumab received vedolizumab SC 108 mg every 2 weeks during the VISIBLE OLE study.

Vermeire and colleagues evaluated safety as the primary endpoint. Long-term clinical remission and corticosteroid-free clinical remission served as clinical efficacy outcomes.

Results showed adverse events occurred in 69% of patients with UC and serious adverse events occurred in 14% of patients.

Vermeire noted clinical remission rates were maintained from week 6 to week 108 in the VISIBLE 1 randomized completers and from week 14 to week 110 in the nonrandomized week 14 responders. VISIBLE 1 randomized completers maintained corticosteroid-free clinical remission rates from week 52 to week 108 and nonrandomized week 14 responders maintained rates from week 54 to week 110.

“Long-term safety findings of vedolizumab SC was consistent with the known safety profile of vedolizumab,” she said.